Analysis
Ollin Biosciences has agreed to be acquired by Johnson & Johnson for $2.2 billion upfront, with regulatory and commercial milestone payments of up to approximately $1.125 billion on top, J&J said on November 16, 2026 in a press release.
CNBC puts the total at up to $3.33 billion. The deal brings J&J OLN324, which J&J describes as a Phase 3 investigational bispecific antibody for retinal vascular diseases, and is expected to close before the end of 2026, subject to regulatory approvals and customary closing conditions.
A second agreement sits alongside the purchase. Blackstone will pay J&J a total of $750 million over multiple years toward OLN324's development, and in return is eligible for regulatory and sales milestones and single-digit royalties, per the J&J release. That funding only kicks in if the acquisition closes. J&J said the accounting treatment will be communicated on or before closing.
“CNBC puts the total at up to $3.33 billion.”
What Ollin Biosciences does
Ollin is a clinical-stage biopharmaceutical company developing therapies for serious eye diseases. CNBC describes it as a Texas-based biotech established in 2023; Dealroom lists its headquarters as Austin and names co-founder Jason Ehrlich as chief executive. Its lead drug, OLN324, targets two pathways at once, VEGF and Ang2, in a small antibody format J&J calls a minibody, and is being developed for wet age-related macular degeneration and diabetic macular edema. Kip Connor, who leads J&J's ophthalmology disease area, said in the release that the drug could cut retinal fluid more effectively and allow more time between treatments.
How much has Ollin Biosciences raised?
CNBC reports that Ollin raised $330 million in June to fund its trials, the round Pulse covered at the time. Dealroom's company profile adds the earlier round and the marks.
Value Add VC data
- Sep 2025, Series A -- $100M at a $400M valuation, led by ARCH Venture Partners, Mubadala Capital and Monograph Capital (Dealroom)
- Jun 2026, Series B -- $330M at a $1.3B valuation, lead not listed (Dealroom; amount confirmed by CNBC)
- Nov 2026, acquisition -- $2.2B upfront plus up to about $1.125B in milestones, buyer Johnson & Johnson (J&J)
On those figures, the $2.2 billion upfront price is about 1.7 times the $1.3 billion Series B valuation Dealroom lists, and the full $3.33 billion with milestones would be about 2.6 times, five months after that round.
Who invested in Ollin Biosciences?
CNBC names ARCH Venture Partners and Mubadala Capital as Ollin's backers. Dealroom lists ARCH, Mubadala Capital and Monograph Capital as leads of the first $100 million, and Blackstone, CPP Investments, Mubadala Capital and a16z Bio + Health among Series B investors. If Dealroom's list is right, Blackstone sits on both sides of Monday's deal: a Series B investor in Ollin and now J&J's development-funding partner. See our Ollin Biosciences hub for prior coverage.
Retina drug market and competitors
OLN324 is aimed at a market Roche's Vabysmo, itself a VEGF and Ang2 bispecific, already serves. CNBC reports that in an early-stage head-to-head study, OLN324 showed faster and greater improvements in eye structure and greater vision gains than Vabysmo, according to Ollin. Blackstone's life sciences arm has used the same funding playbook before: CNBC notes Pfizer's separate deal with Blackstone for up to $1.5 billion.
The caveat is the evidence. The comparison with Vabysmo comes from an early study reported by the company, not from Phase 3 data, and CNBC says late-stage studies were planned to start in the second half of this year. J&J is paying $2.2 billion for a drug whose pivotal late-stage trials have not yet read out, and roughly a third of the headline value depends on milestones that only pay if OLN324 is approved and sells.